Hormonal
GLP-1 receptor agonists (liraglutide, semaglutide, dulaglutide) produce significant weight loss in obese patients (BMI ≥30 or ≥27 with comorbidities) through mechanisms including delayed gastric emptying, increased satiety, and increased resting energy expenditure.
If you have obesity or overweight with related health issues, GLP-1 medications like liraglutide are a proven, effective treatment. They work by mimicking a hormone that signals fullness and increases energy use, not just by slowing digestion. You take a daily injection, but the significant weight loss and health improvements can be worth it. Always consult a doctor to see if you are a candidate, especially if you have a history of thyroid cancer.
The weight loss associated with GLP-1R analogues is thought to be achieved through a variety of mechanisms, including delayed gastric emptying, increased satiety, and increased resting energy expenditure, as well as direct effects on the appetite center of the brain
Why this rating
Based on multiple RCTs (SCALE studies) showing statistically significant weight loss.
Source
Pharmacological Support for the Treatment of Obesity—Present and Future
Marcin Kosmalski et al. · Healthcare · 2023
DOI 10.3390/healthcare11030433
More from this paper
- Orlistat reduces body weight by inhibiting gastric and pancreatic lipases, thereby reducing the absorption of dietary fats, with efficacy demonstrated in obese patients.Good
- The combination of bupropion and naltrexone reduces body weight by stimulating POMC neurons to decrease energy intake and increase expenditure, with naltrexone blocking negative feedback to enhance this effect.Good
- The combination of phentermine and topiramate is highly effective for weight reduction, particularly in patients with compulsive overeating or bulimia nervosa, by reducing food intake through central mechanisms.Good
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →